Kamada Ltd.

KMDA

IL0010941198

Pharmaceuticals

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 07:24:09 2024-04-25 am EDT			5-day change	1st Jan Change
1,938 ^ILa	-2.42%		+1.52%	-12.98%

Mar. 06	Transcript : Kamada Ltd., Q4 2023 Earnings Call, Mar 06, 2024
Mar. 06	Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index

August 12, 2021 at 12:00 am EDT

Kamada Ltd. has been removed from TA-125 Index.

Latest news about Kamada Ltd.

Transcript : Kamada Ltd., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Kamada Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Kamada Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Kamada Ltd. Provides Revenue Guidance for the Year 2024	Mar. 06	CI
Kamada, Kedrion Extend US Distribution Deal for Kedrab	Dec. 07	MT
Kamada Amends, Extends Kedrab Distribution Deal With Kedrion Biopharma; Shares Surge 20% Pre-Bell	Dec. 06	MT
Transcript : Kamada Ltd. - Special Call	Dec. 06
Top Premarket Gainers	Dec. 06	MT
Kamada Ltd. Announces the Execution of A Binding Memorandum of Understanding with Kedrion	Dec. 06	CI
Transcript : Kamada Ltd., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Kamada Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Kamada Says Cytogam Produced in Israel Plant Available for Sales in US	23-10-16	MT
Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data	23-10-16	CI
Kamada Files For $50 Million Share Offering	23-09-11	MT
Transcript : Kamada Ltd., Q2 2023 Earnings Call, Aug 16, 2023	23-08-16
Kamada Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023	23-08-16	CI
Kamada Ltd. Announces Kedrion Exercised Its Option for Two-Year Extension of Kedrion Distribution Agreement in the U.S	23-07-12	CI
Kamada Ltd. announced that it expects to receive $60 million in funding from First Israel Mezzanine Investors Ltd.	23-05-22	CI
Transcript : Kamada Ltd., Q4 2022 Earnings Call, Mar 15, 2023	23-03-15
Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022	22-08-17	CI
Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index	21-08-12	CI
KAMADA : Chardan Suspends Coverage on Kamada at Buy Rating With $11 Price Target	21-08-02	MT
Kamada : Rabies Therapy Gets US FDA Approval for Label Update for Use in Treating Children	21-06-02	MT
Kamada : Amends GLASSIA License Contract with Takeda	21-04-07	MT

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
KAMADA LTD.	-12.98%	292M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals

Kamada Ltd.

Equities

KMDA

IL0010941198

Pharmaceuticals

Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index

Latest news about Kamada Ltd.

Chart Kamada Ltd.

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals